Drug Profile

QR 059

Alternative Names: QR-059

Latest Information Update: 23 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

23 Jun 2025 Phase-II clinical trials in Paroxysmal nocturnal haemoglobinuria (unspecified route) before June 2025 (Wuhan Createrna Science and Technology pipeline, June 2025)
06 Jul 2022 Wuhan Createrna Science and Technology plans to file an IND application for IgA nephropathy and Paroxysmal nocturnal haemoglobinuria (Wuhan Createrna Science and Technology pipeline, July 2022)
20 Dec 2021 Preclinical trials in IgA nephropathy in China (unspecified route) before December 2021 (Wuhan Createrna Science and Technology pipeline, December 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com